木曜日、Eli Lilly and Company (ニューヨーク証券取引所: LLY) は第2四半期の決算を発表し、MounjaroとZepboundという大ヒット糖尿病治療薬および減量注射剤の人気...
ログインすると全部閲覧できます。
ログイン
On Thursday, Eli Lilly and Company (NYSE:LLY) reported its second quarter results, smashing estimates fueled by the popularity of its blockbuster diabetes drug Mounjaro and weight loss injection Zepbound. Without giving any specific details, the pharmaceutical company did reveal it reached several supply related milestones during the quarter. The second quarter results reflect Eli Lilly's leading position in the lucrative weight loss field, which even the mighty Pfizer Inc (NASDAQ:PFE) is struggling to access.
For the second quarter, revenue rose almost 36% to $11.30 billion, fueled by the success of Mounjaro and Zepbound, the type...
木曜日、Eli Lilly and Company (ニューヨーク証券取引所: LLY) は第2四半期の決算を発表し、MounjaroとZepboundという大ヒット糖尿病治療薬および減量注射剤の人気...
ブラウザの共有ボタンを使って、このページを友人と共有することができます。